Literature DB >> 14585277

Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates.

Daniela Verthelyi1, Dennis M Klinman.   

Abstract

Oligodeoxynucleotides (ODN) containing CpG motifs mimic the ability of microbial DNA to activate the innate immune system. The resultant response limits the early spread of infectious organisms while promoting the development of adaptive immunity. CpG ODN show promise as vaccine adjuvants and in the treatment of asthma, allergy, infection, and cancer. Due to evolutionary divergence in CpG recognition between species, CpG ODN that are most active in rodents are poorly immunostimulatory in primates. Thus, evidence that CpG ODN have therapeutic activity in mice must be confirmed in primates. Two distinct types of CpG ODN were identified that stimulate primate PBMC. D-type ODN trigger plasmacytoid DC to secrete IFNalpha, monocytes to mature into functionally active DC, and NK cells to secrete IFNgamma. K-type ODN stimulate B cells and monocytes to proliferate and secrete IgM, IL-10, and/or IL-6. In vivo studies in nonhuman primates indicate that proinflammatory or humoral immune responses can be selectively facilitated by judicious use of these distinct types of ODN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585277     DOI: 10.1016/s1521-6616(03)00202-x

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  20 in total

1.  Inhibition of murine allergic airway disease by Bordetella pertussis.

Authors:  Young-Suk Kim; Keun-Sang Kwon; Dae-Ki Kim; Il-Whan Choi; Hern-Ku Lee
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

2.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

3.  Assessing the immunopotency of Toll-like receptor agonists in an in vitro tissue-engineered immunological model.

Authors:  Yifan Ma; Louis Poisson; Guzman Sanchez-Schmitz; Santosh Pawar; Chunfeng Qu; Gwendalyn J Randolph; William L Warren; Eric M Mishkin; Russell G Higbee
Journal:  Immunology       Date:  2010-03-17       Impact factor: 7.397

4.  CpG oligodeoxynucleotide 2006 and miltefosine, a potential combination for treatment of experimental visceral leishmaniasis.

Authors:  Suman Gupta; Shraddha A Sane; Nishi Shakya; Preeti Vishwakarma; W Haq
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

5.  The acceleration of wound healing in primates by the local administration of immunostimulatory CpG oligonucleotides.

Authors:  Masaki Yamamoto; Takashi Sato; Joel Beren; Daniela Verthelyi; Dennis M Klinman
Journal:  Biomaterials       Date:  2011-03-21       Impact factor: 12.479

6.  An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.

Authors:  Lissette S Velasquez; Brooke E Hjelm; Charles J Arntzen; Melissa M Herbst-Kralovetz
Journal:  Clin Vaccine Immunol       Date:  2010-10-20

7.  Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells.

Authors:  Kristina Abel; Yichuan Wang; Linda Fritts; Eleonora Sanchez; Eugene Chung; Patricia Fitzgerald-Bocarsly; Arthur M Krieg; Christopher J Miller
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

8.  CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection.

Authors:  Jane C Deng; Thomas A Moore; Michael W Newstead; Xianying Zeng; Arthur M Krieg; Theodore J Standiford
Journal:  J Immunol       Date:  2004-10-15       Impact factor: 5.422

9.  Intranasal immunization with chlamydial protease-like activity factor and CpG deoxynucleotides enhances protective immunity against genital Chlamydia muridarum infection.

Authors:  Yu Cong; Madhulika Jupelli; M Neal Guentzel; Guangming Zhong; Ashlesh K Murthy; Bernard P Arulanandam
Journal:  Vaccine       Date:  2007-02-23       Impact factor: 3.641

10.  Prolonged protection against Intranasal challenge with influenza virus following systemic immunization or combinations of mucosal and systemic immunizations with a heat-labile toxin mutant.

Authors:  Fengmin Zhou; Amanda Goodsell; Yasushi Uematsu; Michael Vajdy
Journal:  Clin Vaccine Immunol       Date:  2009-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.